MBiotech student publishes on clinical trial failure rate in Lymphoma

Clinical Trial Risk in Non-Hodgkin's Lymphoma: Endpoint and Target Selection

Ms. Zoe Zhang conducted research on clinical trail failure rates in lymphoma while an MBiotech student.  Her work has now been published in a peer reviewed journal and is entitled "Clinical Trial Risk in Non-Hodgkin's Lymphoma:  Endpoint and Target Selection".  The study found that only 8-11% of drugs for non-hodgkin's lymphoma were on average approved by the FDA in the US.  The study suggested that secondary outcome measures such as overall survival are more predictive than surrogate primary outcome measures.   

The project was supervised by Dr. Jayson Parker and in collaboration with Dr. Rena Buckstein, head of hematology at Sunnybrook hospital.  Zoe is now working at the Genomics institute in China, an exciting emerging market. 

The article link:  http://ejournals.library.ualberta.ca/index.php/JPPS/index